Keyword Search
 
2017
DateTitle 
06/28/17Aileron Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, today announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Aileron. In addition, Aileron has granted the und... 
Printer Friendly Version
06/15/17Aileron Therapeutics Appoints Donald Dougherty as Senior Vice President and Chief Financial Officer
CAMBRIDGE, MA—June 15, 2017—Aileron Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, today announced the appointment of Donald Dougherty as senior vice president and chief financial officer, effective June 8th.Mr. Dougherty joins Aileron with more than 30 years of financial leadership experience. He founded Compound Capital Growth Investments (CCGrowth), LLC, a Boston investment firm focused ... 
Printer Friendly Version
06/03/17Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
First clinical data reported on a dual inhibitor of MDMX and MDM2,key suppressors of P53 functionData reviewed in oral presentation at 2017 ASCO Annual MeetingCHICAGO, IL—June 3, 2017—Aileron Therapeutics, a clinical-stage biopharmaceutical companydeveloping a novel class of therapeutics called stapled peptides, today announced safety andclinical activity data, including complete responses, partial responses and evidence of stabledisease, from its Phase 1, multi-center trial with ALRN-6924 in a ... 
Printer Friendly Version
05/18/17Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53
Abstract also selected for inclusion in the Best of ASCO® ProgramP53 stapled peptide product candidate ALRN-6924 granted orphan drug designation from FDAfor treatment of acute myeloid leukemiaCAMBRIDGE, MA—May 18, 2017—Aileron Therapeutics, a clinical-stage biopharmaceuticalcompany advancing a novel class of therapeutics called stapled peptides, today announced thatthe Company's abstract for ALRN-6924, its lead stapled peptide product candidate targetingp53, was selected for an oral presentation... 
Printer Friendly Version